Drug intelligence / Profile preview

epirubicinol

Development stage: Unknown
Modality: Small Molecules

Overview

Epirubicinol is a major active metabolite of epirubicin (an anthracycline chemotherapy agent); epirubicinol is formed in vivo by the reduction of the carbonyl group at the 13-position of epirubicin. Epirubicinol may contribute to the overall pharmacological and toxic effects of epirubicin. The mechanism of action for epirubicinol is presumed to be similar to epirubicin, which includes DNA intercalation, inhibition of topoisomerase II, generation of free radicals, and disruption of nucleic acid and protein synthesis in rapidly dividing cells. Epirubicin and its metabolites are used as cytotoxic agents mainly for the treatment of several cancers, notably breast and bladder cancer.

Other names: 7-deoxy-7-hydroxyepirubicinepirubicinol

Targets

TOP2B (DNA topoisomerase II beta)DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on epirubicinol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epirubicinol.

Explore the full profile